Drug-eluting stents work as well as bare-metal stents at keeping blocked arteries open, according to a meta-analysis in the April 23 Archives of Internal Medicine. Additionally, drug-eluting stents dont increase the risk of death, and theyre more likely to prevent narrowing of the arteries than bare-metal stents. Researchers analyzed records from 11 clinical trials involving a total of 6,551 patients; approximately two-thirds had been fitted with drug-eluting stents and one-third with bare-metal stents. About a year after the stents were placed, there were no significant differences between groups in the risks of death, stent thrombosis, or heart attack recurrence. However, patients with drug-eluting stents required revascularization nearly half as often as those with bare-metal stents. The results, write the authors, provide strong evidence of the beneficial effects of drug-eluting stents compared with bare-metal stents. ...

TY - JOUR. T1 - Comparison of Coronary Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Patients With Diabetes Mellitus. AU - Briguori, Carlo. AU - Condorelli, Gerolama. AU - Airoldi, Flavio. AU - Focaccio, Amelia. AU - DAndrea, Davide. AU - Cannavale, Mario. AU - Abarghouei, Alireza Afzali. AU - Giordano, Salvatore. AU - De Vivo, Fabrizio. AU - Ricciardelli, Bruno. AU - Colombo, Antonio. PY - 2007/3/15. Y1 - 2007/3/15. N2 - We compared 1-year outcome after drug-eluting stent (DES) implantation with off-pump bypass grafing (OPCABG) in patients with type 2 diabetes mellitus and multivessel coronary artery disease involving the proximal segment of the left anterior descending coronary artery. All consecutive diabetic patients treated by DES (DES group) or OPCABG (CABG group) in our institution from April 2002 to December 2004 because of de novo coronary lesions were included. Patients in the CABG group (n = 149) were older and had a higher rate of 3-vessel disease than those in the ...

TY - JOUR. T1 - Predictors for very late stent thrombosis after drug-eluting stent implantation in diabetic patients. AU - Voudris, Vassilis. AU - Kariofillis, Panagiotis. AU - Thomopoulou, Sophia. AU - Patsilinakos, Sotiris. AU - Manginas, Athanasios. AU - Spargias, Constantinos. AU - Pavlides, Gregory. AU - Cokkinos, Dennis V.. PY - 2009/1. Y1 - 2009/1. N2 - Aims: Despite encouraging results with drug-eluting stents (DES) reported in diabetic patients, the longterm safety is unknown because of very late stent thrombosis (VLST). We investigated the incidence, risk factors and clinical manifestations of VLST in diabetic patients treated with DES, during long-term clinical follow-up. Methods and results: A total of 610 consecutive diabetic patients underwent PCI with DES. Dual antiplatelet treatment (APLT) for 12 months received 93%, more than 12 months 72% and statin treatment 93% of patients. Clinical follow-up of at least 12 months post DES implantation was obtained in 597/610 (98%) patients. ...

Patients who have undergone coronary bypass surgery have had a vein removed from the leg and implanted in the chest to bypass blockages in the coronary arteries. These veins are called saphenous vein grafts or SVGs. SVGs often develop blockages that can cause chest pain and heart attacks. SVG blockages can be opened by using small balloons and stents (metal coils that keep the artery open). Two types of stents are currently used: bare metal stents (BMS) and drug-eluting stents (DES). Both BMS and DES are made of metal. DES are also coated with a drug that releases into the wall of the blood vessel to prevent scar tissue from forming and re-narrowing the vessel. Both stents have advantages and disadvantages: DES require taking special blood thinners (called thienopyridines, such as clopidogrel or prasugrel) longer than bare metal stent and could have more bleeding but are also less likely to renarrow. Both BMS and DES are routinely being used in SVGs, but it is not known which one is better. ...

Patients who have undergone coronary bypass surgery have had a vein removed from the leg and implanted in the chest to bypass blockages in the coronary arteries. These veins are called saphenous vein grafts or SVGs. SVGs often develop blockages that can cause chest pain and heart attacks. SVG blockages can be opened by using small balloons and stents (metal coils that keep the artery open). Two types of stents are currently used: bare metal stents (BMS) and drug-eluting stents (DES). Both BMS and DES are made of metal. DES are also coated with a drug that releases into the wall of the blood vessel to prevent scar tissue from forming and re-narrowing the vessel. Both stents have advantages and disadvantages: DES require taking special blood thinners (called thienopyridines, such as clopidogrel or prasugrel) longer than bare metal stent and could have more bleeding but are also less likely to renarrow. Both BMS and DES are routinely being used in SVGs, but it is not known which one is better. ...

Press Release issued Oct 28, 2012: TechNavios analysts forecast the Global Drug-eluting Stents market to reach US$6,278 million by 2015. One of the key factors contributing to this market growth is the increasing incidence of cardiovascular diseases. The Global Drug-eluting Stents market has also been witnessing the use of bifurcated self-expanding coronary stents. However, the decline in the average selling price of drug-eluting stents could pose a challenge to the growth of this market.

The study found that drug-eluting balloons were the least costly strategy for payers: 21% and 26% lower costs than drug-eluting stents and bare metal stents respectively. The study also found that switching even 50% of current angioplasty cases from percutaneous transluminal angioplasty to a drug-eluting balloon strategy could lead to an annual cost reduction of US$250 million to US Medicare.. Similarly an economic assessment of drug-eluting balloon vs. percutaneous transluminal angioplasty in a Swiss University Hospital found that over a one-year period percutaneous transluminal angioplasty cost around 90,000 Swiss francs more than drug-eluting balloon therapy due to repeat intervention costs, despite the greater initial acquisition costs associated with drug-eluting balloons. And yet, percutaneous transluminal angioplasty reimbursement is approximately 154,000 Swiss francs more than for drug-eluting balloons from the physician/facility provider perspective.. Zeller explained that there were ...

Drug-eluting stents reduce clinical events related to restenosis but may be complicated by late stent-thrombosis. Whereas assessment of target-vessel ischemia by myocardial perfusion scintigraphy identifies relevant restenosis noninvasively, it is unknown whether this technique may also predict late clinical events related to late stent-thrombosis and to restenosis after drug-eluting stent implantation. METHODS: All 826 patients treated with stenting between May 2003 and May 2004 were included in the Basel Stent Cost Effectiveness Trial (Basel Stent Kosten-Effektivitäts Trial, or BASKET) and randomized (2:1) to drug-eluting stents or bare metal stents. Myocardial scintigraphy was performed on 476 (64%) of 747 patients without major events after 6 mo. Patients were followed for 1 y for cardiac death, nonfatal myocardial infarction, and target-vessel revascularization due to restenosis or late stent-thrombosis. RESULTS: The rate of target-vessel ischemia in these patients was lower with ...

Despite the success of coronary stent implantations in the last decade, in-stent restenosis due to neointimal hyperplasia remains a problem to overcome. Neointimal hyperplasia is a vascular response to stent injury and mainly consists of proliferation of smooth muscle cells and deposition of extracellular matrix. Recently, local drug delivery has been advocated as a potential strategy to prevent in-stent restenosis. Unprecedented results have been obtained in early clinical studies on sirolimus-eluting and paclitaxel-eluting stents. Trials using various pharmaceutical coatings on different coronary stents are ongoing. More types of drug-eluting stents are expected on the market in the near future. Meanwhile, the evaluation of drug-eluting stents is entering the second phase in which the safety and efficacy in more complex lesion subsets and different clinical presentations are being investigated. Results including cost-benefit analyses are expected to have a tremendous impact on the practice of ...

Definite stent thrombosis definition maximizes specificity, but it may be insufficiently sensitive to capture completely this relatively rare event. Sensitivity can be increased by including probable stent thrombosis in the analysis. There is limited head-to-head data on late stent thromboses for drug-eluting stents with biodegradable polymers. In accordance with the Academic Research Consortium we assessed definite and probable stent thrombosis events in the SORT OUT VII trial, among patient treated with the thin strut cobalt-chromium sirolimus-eluting Orsiro stent (Biotronik, Bülach, Switzerland) and the stainless steel biolimus-eluting Nobori stents (Terumo, Tokyo, Japan). ...

I read with interest the article entitled Comparison of Percutaneous Coronary Intervention With Bare-Metal and Drug-Eluting Stents for Cardiac Allograft Vasculopathy (1). This is an interesting study showing a lower in-stent restenosis rate of patients receiving drug-eluting stents (DES) for allograft vasculopathy. There are 2 major points that need clarification. The authors did not report any statistical analysis in regards to important end points such as death, myocardial infarction, or target vessel revascularization in each group. We have to assume that these very important end points, including re-transplantation, were similar between the groups. Death and re-transplantation occurred in 34% of the entire cohort with follow-up of ,1 year. This suggests poor prognosis of patients with significant allograft vasculopathy, regardless of stent types used. This is an important observation that needs to be emphasized. The second important point concerns a major dilemma that exists between ...

Use of drug-eluting stents is associated with a lower risk of major cardiovascular events at one year compared to bare metal stents when followed by an individualized course of blood-thinning medication among patients previously thought to be uncertain candidates for drug-eluting stents due to their heightened risk of bleeding or blood clots, according to research presented at the American College of Cardiologys 63rd Annual Scientific Session.

Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial.. The randomized, controlled BioSTEMI trial was the first direct comparison between the two drug-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI). Biotronik announced the results at the European Society of Cardiology Congress in Paris. In 2016, Berlin-based Biotronik claimed the Orsiro device had the edge over Xience in a heart attack subgroup study.. The 12-month study at Geneva University Hospitals included 1,300 patients with acute myocardial infarction. Orsiro had an incidence of 4% target lesion failure (TLF) at 12 months compared to Xiences 6%. The difference in TLF was caused by lower rates of clinically indicated target lesion revascularization in patients treated with Orsiro, compared to Xience. The results were published in The Lancet.. The BioSTEMI trial proves what the ...

Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel inflammation, a biologically active endothelium with strut coverage similar to a bare metal stent, and inhibition of intimal hyperplasia comparable to that seen with sirolimus-eluting stents. The SPIRIT family of clinical trials demonstrated low rates of late loss, and clinical restenosis, as well as low rates of very late stent thrombosis. These excellent clinical outcomes addressed limitations of the 1st generation DES, and substantiated widespread clinical use of the EES platform.

Second generation drug-eluting stents are safe and effective in treatment of left main coronary artery disease. A study found that second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions. Results of the ISAR-LEFT MAIN 2 trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the worlds premier educational meeting specializing in interventional cardiovascular medicine.. Patients undergoing invasive treatment of unprotected left main coronary artery (uLMCA) lesions are often considered at high-risk of adverse cardiovascular events. The use of first generation drug-eluting stents in these lesions has previously been shown to be feasible, safe, and effective. The second-generation zotarolimus-eluting (ZES) and everolimus-eluting stents (EES), used more widely in clinical practice at present, perform very similarly in ...

TY - JOUR. T1 - Drug-eluting stent thrombosis in routine clinical practice two-year outcomes and predictors from the Taxus arrive registries. AU - Lasala, John M.. AU - Cox, David A.. AU - Dobies, David. AU - Baran, Kenneth. AU - Bachinsky, William B.. AU - Rogers, Edwin W.. AU - Breall, Jeffrey A.. AU - Lewis, David H.. AU - Song, Aijun. AU - Starzyk, Ruth M.. AU - Mascioli, Stephen R.. AU - Dawkins, Keith D.. AU - Baim, Donald S.. N1 - Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 2009/8. Y1 - 2009/8. N2 - Background-Stent thrombosis (ST) is an uncommon but serious complication of drug-eluting and bare metal stents. To assess drug-eluting stent ST in contemporary practice, we analyzed 2-year data from the 7492-patient ARRIVE registry. Methods and Results-Patients were enrolled at the initiation of percutaneous coronary intervention with no inclusion/ exclusion criteria beyond use of the paclitaxel-eluting TAXUS stent. Two-year follow-up was 94% with independent ...

Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results ...

physicians must be cautious in how they use drug-eluting stentsA statement warning cardiologists when treating arteries with drug-eluting stents was issued by The Society for Cardiovascular Angiography and Interventions (SCAI).The SCAI supports use of drug-eluting stents, but stated that physicians must be cautious in how they use them. Doctors need to carefully select patients who would benefit...

I read with interest the results of the paper by Giustino et al. (1) to evaluate the safety and efficacy of new-generation drug-eluting stents in women undergoing complex percutaneous coronary artery revascularization. I wish to congratulate the investigators on undertaking this piece of work in such a large cohort (n = 10,241) to help us improve our understanding of the outcomes of percutaneous coronary intervention in women. I was particularly encouraged to see improved results for newer drug-eluting stent platforms in terms of reducing major adverse cardiac events (defined as the composite of all-cause mortality, myocardial infarction, and target lesion revascularization at 3 years).. However, one of the concerns when treating women is the risk for bleeding, particularly when faced with patients who may be older and of relatively low weight compared with their male counterparts. This is reflected in bleeding risk predictor scores, which include female sex as an important predictive factor ...

BIOTRONIK announced today market approval for its Orsiro1 coronary drug-eluting stent (Orsiro DES) by the Japanese Ministry of Health. This was supported by the positive 12-month outcomes of the BIOFLOW-IV clinical study which were presented at the 81st Japan Circulation Society congress. The BIOFLOW-IV study is a prospective multi-center, inter...

The development of bare-metal stents (BMS) was the second revolution in the percutaneous coronary interventional cardiology field. Stents addressed acute vessel closure and lowered the risk of target lesion revascularization (TLR). However, BMS were particularly prone to in-stent restenosis, predominantly due to neointimal hyperplasia. Following the failure of a number of treatment options to lower restenosis,1,2 drug-eluting stents (DES) provided the answer. The first-generation DES dramatically reduced TLR rates, but they were associated with the increased risk of late and very late stent thrombosis.3,4 Second-generation stents have safely overcome the limitations of BMS and first-generation DES with extremely low rates of target lesion failure and a reduction in stent thrombosis rates seen with first generation DES. These goals are now achieved without the need to prolong dual antiplatelet therapy (DAPT) when dealing with a stable patient. Therefore, current-generation DES should be the gold ...

TY - JOUR. T1 - Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations. Results From the COBIS (Coronary Bifurcation Stenting) Registry. AU - Song, Young Bin. AU - Hahn, Joo Yong. AU - Choi, Seung Hyuk. AU - Choi, Jin Ho. AU - Lee, Sang Hoon. AU - Jeong, Myung Ho. AU - Kim, Hyo Soo. AU - Seong, In Whan. AU - Yang, Ju Young. AU - Rha, Seung Woon. AU - Jang, Yangsoo. AU - Yoon, Jung Han. AU - Tahk, Seung Jea. AU - Seung, Ki Bae. AU - Park, Seung Jung. AU - Gwon, Hyeon Cheol. PY - 2010/4/20. Y1 - 2010/4/20. N2 - Objectives: We aimed to compare the long-term clinical outcomes of patients treated with sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) for coronary bifurcation lesions. Background: There are limited data regarding comparisons of SES and PES for the treatment of bifurcation lesions. Methods: Patients who received percutaneous coronary intervention for non-left main bifurcation lesions were enrolled from 16 centers in Korea between January ...

Introduction Drug-eluting stents (DES) have reduced the rates of restenosis to less than 10%; however, increased incidence of late in-stent thrombosis, is now a major clinical problem of using DES for its consequences in terms of morbidity and mortality. Interference with the process of re-endothelialization appears to play a major role in this latent complication. Thus, the search for molecular compounds capable of preventing restenosis that also can reduce the risk of late in-stent thrombosis is of utmost importance. Previously, we have shown that certain non-steroidal anti-inflammatory drugs (NSAIDs) are capable of inhibiting rat vascular smooth muscle cell proliferation, a key element in the process of restenosis post stent deployment. Here, we evaluated whether proliferation and migration of human coronary artery smooth muscle cells (HCASMCs) is reduced by the NSAID, ibuprofen, whether this correlated with changes in the phenotype of HCASMCs and the potential molecular mechanisms involved. ...

TY - JOUR. T1 - Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. AU - Généreux, Philippe. AU - Redfors, Björn. AU - Witzenbichler, Bernhard. AU - Arsenault, Marie Pier. AU - Weisz, Giora. AU - Stuckey, Thomas D.. AU - Rinaldi, Michael J.. AU - Neumann, Franz Josef. AU - Christopher Metzger, D.. AU - Henry, Timothy D.. AU - Cox, David A.. AU - Duffy, Peter L.. AU - Mazzaferri, Ernest L.. AU - Francese, Dominic P.. AU - Marquis-Gravel, Guillaume. AU - Mintz, Gary S.. AU - Kirtane, Ajay J.. AU - Maehara, Akiko. AU - Mehran, Roxana. AU - Stone, Gregg W.. PY - 2017/3/15. Y1 - 2017/3/15. N2 - Background Percutaneous coronary intervention (PCI) of lesions with coronary arterial calcification (CAC) is common and has been historically associated with an increased risk of adverse events. Whether the association between target lesion calcification (CAC) and outcomes differ across drug-eluting stent generation or between patients with high vs. low ...

It was reported that stent explantation occurred. The target lesion was located in the severely calcified left anterior descending (lad) artery. Following pre-dilatation, a 4. 00 x 20 synergy drug-eluting stent was implanted in the mid lad, followed by the implantation of a 4. 00 x 28 synergy drug-eluting stent in the proximal lad. However, it was noted that the proximal lad stent was malapposed and the two stents became stuck. During removal of the proximal lad stent, it got caught in the mid lad stent and both stents were removed from the patient. The procedure was completed with another of the same device. No patient complications were reported and the patients status was stable. ...

A pooled analysis of safety data from Medtronics Endeavor clinical programme has affirmed the superior safety of the Endeavor drug-eluting coronary stent compared to the best-in-class Medtronic bare metal stent, Driver.

TechNavios analysts forecast the Drug-eluting Stent market in Europe to grow at a CAGR of 4.3 percent over the period 2011-2015. One of the key factors contributing to this market growth is the high prevalence of cardiovascular diseases in the region. The Drug-eluting Stent market in Europe has also been witnessing the trend of formation of strategic alliances among vendors. However, the decline in the average price of drug-eluting stent could pose a challenge to the growth of this market.. TechNavios report, the Drug-eluting Stent Market in Europe 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on Europe; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.. Key vendors dominating this market space include Boston Scientific Corp., Abbott Vascular, Medtronic Inc., and Cordis Corp.. ...

Drug-Eluting Stents Can Cause Serious Consequences. Drug-eluting stents have greatly reduced the risk of repeat blockage of heart disease.

Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008 Jun; 1(3):227-32 ...

Cypher data were so unequivocal that the FDA panel reviewing the data issued a unanimous recommendation for approval in the fall of 2002. In fact, Cypher appeared to be so effective that the Centers for Medicare and Medicaid Services took the unprecedented step of approving payment prior to the official FDA approval and launch that occurred in late April 2003. Cypher had been approved in Europe in early 2002; Taxus was released there earlier this year.. Cardiologists appear to favor the eluting stents over the bare metal stents. This preference will allow the drug-eluting stents to overtake the traditional bare metal version rapidly. In fact, Wall Street analysts predict that by the end of 2003, eluting stents will have 40 percent of the market.. Although promising to reduce the restenosis rate even further, these stents, too, are not without drawbacks. Cypher has a list price of $3,195 per stent (any size or length); several times the cost of the bare metal stents, which have decreased in price ...

Although drug-eluting stents dramatically reduce stent restenosis, in-stent restenosis still occurs in approximately 10% of sirolimus-eluting stent (SES) implantation cases. Optical coherence tomography (OCT) has the potential to assess neointima hyperplasia precisely in vivo (1). However, the morphological features of stent fracture in OCT imaging have not yet been reported, and there is no OCT study that clarifies the relationship between stent fracture and neointimal hyperplasia in SES. We investigated the morphological features of stent fracture in OCT to clarify the relationship between stent fracture and neointimal hyperplasia in SES.. We enrolled 110 adequately expanded SES (BxVelocity platform) stents from 70 patients. For overlapped stents (n = 41), we confirmed complete overlapping in the post-procedural angiography. The scheduled coronary angiography and OCT imaging were performed at 11 ± 6 months after SES implantation. According to the presence of stent fracture in breath-hold ...

no one suspected the results from the new study, said Morton Kern, a professor of medicine at UC Irvine. It is one other potential downside to drug-eluting stents, Kern said. The study likely will focus more attention on the process of collateral blood-vessel formation as well as developing new generations of drug-coated stents that dont hinder that process, he said. When drug-coated stents became popular in 2003, they were heralded as a major breakthrough in treating heart disease. The tiny, expandable mesh-like tubes were shown to be far superior to bare-metal stents in preventing the gradual reblockage of arteries, a troubling but seldom fatal process known as restenosis. Drug-coated stents are covered by medicine that slowly dissolves and that can dramatically reduce the formation of scar tissue that can re-block an artery. About 1 million Americans are implanted with stents each year and an estimated 80 percent of those devices are drug-coated. However, in recent months researchers and ...

Compared with the currently available fi rst-generation On the basis of results from randomised trials with drug-eluting stents, second-generation drug-eluting strict inclusion and exclusion criteria, fi rst-generation stents have been designed with the goal of improving drug-eluting stents, coated with sirolimus or paclitaxel, cacy, and device performance. Everolimus, a were approved for clinical use in patients with coronary semisynthetic sirolimus analogue, is released from a thin artery disease.1-3 Early experience with use of fi rst- coating of a biocompatible fl uoropolymer on an open generation stents in patients in real-life practice showed cell, thin-strut, cobalt-chromium frame. A signifi cant that benefi t, in terms of the need for reintervention, reduction in serious adverse cardiac events was noted in was most apparent in those with high risk of restenosis.4 patients with the everolimus-eluting stent compared with Widespread use of fi rst-generation drug-eluting stents those ...

Bare-metal coronary stents (BMSs) first appeared in Europe in the 1980s, and by 1994, the U.S. Food and Drug Administration (FDA) had approved 2 BMS devices for commercial use in this country-the first with an indication for bailing out plain old balloon angioplasty (POBA) procedures gone bad, and the second with an indication for reducing the double-digit risk for restenosis with POBA. As percutaneous coronary intervention (PCI) became the preferred method for managing many patients with coronary artery disease and its various manifestations, an increasing level of confidence pervaded the interventional cardiology community. Enthusiasm for PCI was further fueled by the dramatic reduction in the risk for in-stent restenosis-a man-made disease-occurring after BMS implantation with the arrival of drug-eluting stents (DESs). Indeed, DES use increased to more than 80% of all PCI procedures within the first year after FDA approval (1). At present, at least 1 DES is used in 70% of all patients ...

Background: There are few studies which compare the efficacy and safety of the Resolute Onyx zotarolimus-eluting stent (O-ZES) and everolimus-eluting stent (EES) in patients with acute myocardial infarction (AMI). Therefore, the present study aimed to compare clinical outcomes of O-ZES and EES in patients with AMI undergoing successful percutaneous coronary intervention (PCI). Methods: From January 2016 to December 2016, the Korea Acute Myocardial Infarction Registry (KAMIR) enrolled 3,364 consecutive patients. Among them, O-ZES was used in 402 patients and EES was used in 1,084 patients. The primary endpoint was target lesion failure (TLF), as defined by composite of cardiac death, target vessel myocardial infarction (TV-MI), and ischemic driven-target lesion revascularization (ID-TLR) at 6 month clinical follow-up. Results: At 6 months, the incidence of TLF was not significantly different between O-ZES and EES group (4.0% vs. 3.9%, adjusted hazard ratio [HR] 1.17, 95% confidential interval ...

To our knowledge, this is the first report of the use of DES in the intracranial vasculature with angiographic and clinical follow-up. In this series, the use of DES was feasible and safe, because there were no untoward effects associated with the stents. The midterm safety of these devices appears to be favorable with no evidence of arterial toxicity. Importantly, there have been no delayed recurrent ischemic events or cases of stent thrombosis over a mean of 11.1 months of follow-up.. The use of DES in the intracranial vasculature is desirable because of the high restenosis risk (≈32%) associated with bare metal stents (BMS).1 In the Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries trial of a BMS developed for intracranial stenoses, restenosis was associated with a 39% rate of recurrent symptoms.1 Drug-eluting stents have revolutionized the treatment of CAD by reducing the risk of instent stenosis from 30% to ≈5%, and they should have a similar ...

Stents have been used for over a decade to treat coronary arteries affected by stenosis, a state in which the arteries are narrowed by the deposition of plaque. However, studies have shown that a few years after placement of a stent, restenosis can occur at the site, hindering its purpose. Drug-eluting stents (DES) have a significant impact in treating in-stent restenosis. DES are embedded with drugs like Sirolimus that are released over time once the stent is placed within the artery, reducing the chance of plaque deposition around the stent. But DES increases the risk of thrombosis, formation of blood clots around the stent due to a change in the blood flow profile. To improve the DES characteristics, femtosecond pulsed lasers are used to create nano-textures on the metallic stents. Nano-textures increase the availability of the drug, increase adhesion of the drug and the stent, and minimize requirement of a polymer carrier. If the nano-textured materials can show effective fluid retention ...

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc.announced today that voclosporin is positioned to enter a Phase 1clinical trial as the drug utilized in the CINATRA(TM)...

PARIS--(BUSINESS WIRE)--May 16, 2012-- Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing statistically significant advantages of using an IN.PACT drug-eluting balloon from Medtronic, Inc. (NYSE: MDT) over a corresponding conventional treatment for coronary and peripheral artery disease.. Medtronic IN.PACT drug-eluting balloons received CE (Conformité Européenne) mark in 2008 and 2009 and are available in many countries around the world. They are not commercially available in the United States.. BELLO The physician-initiated BELLO (Balloon Elution and Late Loss Optimization) study enrolled 182 patients across 15 hospitals in Italy to evaluate the safety and effectiveness of the Medtronic IN.PACT Falcon(TM) drug-eluting balloon versus the Taxus drug-eluting stent (DES) from Boston Scientific Corp. in reducing late lumen loss in small-vessel coronary artery disease. With both devices eluting ...

The objective of this study is to assess 3-year clinical outcome of patients with true bifurcation lesions (TBLs) versus non-true bifurcation lesions (non-TBLs) following treatment with second-generation drug-eluting stents (DES). TBLs are characterized by the obstruction of both main vessel and side-branch. Limited data are available on long-term clinical outcome following TBL treatment with newer-generation DES. We performed an explorative sub-study of the randomized TWENTE trial among 287 patients who had bifurcated target lesions with side-branches ≥2.0 mm. Patients were categorized into TBL (Medina classes: 1.1.1; 1.0.1; 0.1.1) versus non-TBL to compare long-term clinical outcome. A total of 116 (40.4 %) patients had TBL, while 171 (59.6 %) had non-TBL only. Target-lesion revascularization rates were similar (3.5 vs. 3.5 %; p = 1.0), and definite-or-probable stent thrombosis rates were low (both ,1.0 %). The target-vessel myocardial infarction (MI) rate was 11.3 versus 5.3 % (p = 0.06), ...

Drug-eluting stents are accepted as mainstream endovascular therapy, yet concerns for their safety may be under-appreciated. While failure from restenosis has dropped to below 5%, the risk of stent thrombosis and associated mortality remain relatively high. Further optimization of drug release is required to minimize thrombosis risk while maintaining therapeutic dose.. The complex three-dimensional geometry of deployed stents together with the combination of diffusive and advective drug transport render an intuitive understanding of the situation exceedingly difficult. In situations such as this, computational modeling has proven essential, helping define the limits of efficacy, determine the mode and mechanism of drug release, and identify alternatives to avoid toxicity.. A particularly challenging conformation is encountered in coronary arteries with overlapping stents. To study hemodynamics and drug deposition in such vessels we combined high-resolution, multi-scale ex vivo computed ...

Percutaneous coronary interventions are recognized techniques to treat coronary artery disease. However, despite the progress in the development of materials and techniques, several limitations affect the acute and long-term performance of these procedures. In particular, there are three mayor drawbacks: restenosis, thrombosis and technical feasibility of the procedure. The recent ... read more introduction of drug-eluting stents has been a major step forward in reducing restenosis. The pivotal randomized trials versus bare metal stents, performed in selected patients and lesions, showed a dramatic reduction in restenosis rate with extremely low rates in the drug-eluting stent group. However, a potential issue related to the possibly increased incidence of stent thrombosis with these new devices appeared. Our thesis had two major aims: 1) to assess the values and drawbacks of first-generation drug-eluting stents (eluting sirolimus or paclitaxel) when used in patients and lesions not included in ...

Problem statement: Stent thrombosis, which may occur even one year after stent implantation, is a drawback of Drug-Eluting Stents (DES). Among the variety of causes of stent thrombosis after DES implantation, coronary endothelial dysfunction manifested or exaggerated by DES implantation should not be overlooked. This review article summarizes previous reports on coronary endothelial dysfunction after DES implantation and/or coronary spasm and discusses the mechanism, clinical implications and prognosis. Although novel stents that do not impair endothelial function will most likely be developed in the near future, millions of patients have already undergone implantation of a first or second generation DES. Conclusion/Recommendations: Some studies have reported that a drug improves the impairment of endothelial function. On the other hand, no direct relationships between spasm and stent thrombosis after DES implantation have been reported. A larger study is warranted to clarify the clinical significance

Background: Drug-eluting stents (DES) were used less frequently among black patients when first introduced in 2003. It is unclear whether racial differences persisted as DES diffused.. Methods: We used data from the 2003- 6 Nationwide Inpatient Sample, a multi-state sample of hospitalizations, to identify patients receiving bare metal stents or DES. Analysis was limited to patients age 18 years or older, of black or white race, treated at hospitals with 5 or more PCIs annually (N=374,589). Random-effects logistic regression assessed the independent association of race and DES adjusting for patient and hospital characteristics. Racial differences in DES were partitioned into those attributable to differences in treatment within hospitals (blacks treated differently than whites at the same hospital) and those attributable to differences between hospitals (blacks treated at different hospitals than whites).. Results: Blacks had lower crude rates of DES use than whites in Q2/03 (black-white ...

Results 33 randomised controlled trials involving 31 379 patients with stable coronary artery disease or acute coronary syndrome undergoing DES implantation were retrieved. No differences in mortality among devices were found. In the overall class comparison, second-generation DES were associated with a 22% reduction of odds of MI at short-term OR 0.77 (95% CI 0.68 to 0.89) p=0.0002; EES reduced the odds of definite-probable ST compared with PES: OR 0.33 (95% CI 0.15 to 0.73) p=0.006; First-generation SES along with second-generation EES and ZES-R showed similar efficacy in decreasing the odds of repeat revascularisation.. ...

Nine months after the procedure, the numbers of deaths, heart attacks and repeat interventions required because of renewed blood vessel narrowing were equivalent in both treatment groups (9.2% of patients in the biolimus-eluting stent group and 10.5% of patients in the sirolimus-eluting stent group). In the one in four patients given an angiogram, the degree of blood vessel narrowing at the site of stent implantation was also equivalent in both treatment groups.. The drug-eluting stent is designed to treat narrowing of coronary arteries which is one of the principal causes of coronary artery disease. Once implanted, it uses the strength of its cylindrical mesh wall to keep the artery widened and maintain blood flow, and gradually releases its drug into the surrounding tissues. The role of the drug is to inhibit restenosis, a common problem following stent implantation, whereby excessive tissue forms around the stent and may negate the benefit that it provides. First-generation drug-eluting ...

TY - JOUR. T1 - ComparisOn of neointimal coVerage between zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). AU - Kim, Jung Sun. AU - Kim, Byeong Kuk. AU - Jang, Ik Kyung. AU - Shin, Dong Ho. AU - Ko, Young Guk. AU - Choi, Donghoon. AU - Hong, Myeongki. AU - Cho, Yun Kyeong. AU - Nam, Chang Wook. AU - Hur, Seung Ho. AU - Choi, Jin Ho. AU - Song, Young Bin. AU - Hahn, Joo Yong. AU - Choi, Seung Hyuk. AU - Gwon, Hyeon Cheol. AU - Jang, Yangsoo. PY - 2012/4/1. Y1 - 2012/4/1. N2 - Background: Data on strut surface coverage of second-generation drug-eluting stents (DES) are limited. We investigated stent strut coverage of resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) at 9 months after implantation using optical coherence tomography (OCT). Methods: ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT) is a prospective, randomized, ...

BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO™ Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The company will also stop the manufacture of CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting Coronary Stents by the end of 2011.. Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market, said Seth Fischer, Company Group Chair and Worldwide Chairman, Cordis Corporation. Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. These ...

The long-term safety and efficacy of drug-eluting stent (DES) implantation in the treatment of unprotected left main coronary artery (LMCA) stenosis is still a matter of debate. All consecutive patients (pts) who had sirolimus (SES, Cypher, Cordis, Johnson and Johnson Company, Warren, NJ) or paclitaxel-eluting stent (PES, Taxus, Boston Scientific, Natick, MA) electively implanted in de novo lesions on LMCA between March 2002 and July 2006 were analyzed. A total of 267 patients were treated: 107 with PES and 160 with SES. Sixty-four (23.4%) patients were diabetics, 95 (35.6%) had unstable angina, mean age was 64.5±11.6 years and LVEF 52.2±10.7 %. High mortality risk scores (Euroscore ,6) were present in 84 (31.5%) of the patients. Glycoprotein IIb/IIIa inhibitors were used in 50 (18.7%) patients, 80 (29.9%) underwent intravascular ultrasound. Distal left main lesions were present in 223 (83.5%) of the patients: 209 bifurcations and 14 trifurcations. Both branches were stented in 108 (48.4%) ...

RRISC Trial Reduction of Restenosis In Saphenous vein grafts with Cypher sirolimus-eluting stent Prospective, randomized, double-blind, non industry sponsored, trial comparing sirolimus-eluting stents vs. bare metal stents. Prospective, randomized, double-blind, non industry sponsored, trial comparing sirolimus-eluting stents vs. bare metal stents. 75 patients with 96 lesions localized in 80 diseased saphenous vein grafts were included 75 patients with 96 lesions localized in 80 diseased saphenous vein grafts were included Primary endpoint : in-stent late loss Primary endpoint : in-stent late loss Secondary endpoints: Secondary endpoints:  Clinical events (death, MI, TLR, TVR)  Binary angiographic restenosis in-stent/in-segment  IVUS measured neo-intimal hyperplasia volume

TY - JOUR. T1 - Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population. T2 - A report from the e-SELECT (Multi-center Post-Market Surveillance) registry. AU - Urban, Philip. AU - Abizaid, Alexandre. AU - Banning, Adrian. AU - Bartorelli, Antonio L.. AU - Baux, Ana Cebrian. AU - Davk, Vladimr. AU - Ellis, Stephen. AU - Gao, Runlin. AU - Holmes, David. AU - Jeong, Myung Ho. AU - Legrand, Victor. AU - Neumann, Franz Josef. AU - Nyakern, Maria. AU - Spaulding, Christian. AU - Worthley, Stephen. PY - 2011/3/29. Y1 - 2011/3/29. N2 - Objectives: The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES). Background: Stent thrombosis and MB are major potential complications of drug-eluting stent implantation. Their relative incidence and predisposing factors among large populations treated ...

TY - JOUR. T1 - Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents. T2 - Three-year results of the RAVEL trial. AU - Fajadet, Jean. AU - Morice, Marie Claude. AU - Bode, Christoph. AU - Barragan, Paul. AU - Serruys, Patrick W.. AU - Wijns, William. AU - Constantini, Constantino R.. AU - Guermonprez, Jean Léon. AU - Eltchaninoff, Hélène. AU - Blanchard, Didier. AU - Bartorelli, Antonio. AU - Laarman, Gert Jan. AU - Perin, MarcoAntonio. AU - Sousa, J. Eduardo. AU - Schuler, Gerhard. AU - Molnar, Ferenc. AU - Guagliumi, Giulio. AU - Colombo, Antonio. AU - Hayashi, Ernesto Ban. AU - Wülfert, Egon. PY - 2005/3/1. Y1 - 2005/3/1. N2 - Background - The use of sirolimus-eluting coronary stents has been associated with a nearly complete elimination of restenosis at 6 months and with a very low 1-year incidence of major adverse cardiac events (MACE). This analysis examined whether these beneficial effects persist over the longer term. Methods and Results - This multicenter ...

TY - JOUR. T1 - The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis. T2 - Insights from the e-select 64-71 (multicenter post-market surveillance) registry. AU - Abizaid, Alexandre. AU - Costa, J. Ribamar. AU - Banning, Adrian. AU - Bartorelli, Antonio L.. AU - Dzavik, Vladimir. AU - Ellis, Stephen. AU - Gao, Runlin. AU - Holmes, David R.. AU - Jeong, Muyng Ho. AU - Legrand, Victor. AU - Neumann, Franz Josef. AU - Nyakern, Maria. AU - Orlick, Amy. AU - Spaulding, Christian. AU - Worthley, Stephen. AU - Urban, Philip M.. PY - 2012/1/1. Y1 - 2012/1/1. N2 - This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. There is paucity of consistent data on DES for the treatment of ISR, ...

In 2001, when Morice et al. (1) presented the initial results of RAVEL (The Randomized Study With the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions), showing 0% angiographic restenosis 6 months after implantation of a sirolimus-eluting stent, very few people would have envisaged that more than 10 years later, there would be a need for a trial to evaluate the best treatment strategy for drug-eluting stent (DES) in-stent restenosis (ISR).. Although widespread use of DES (versus bare-metal stents [BMS]), advances in stent design, and greater operator experience have all significantly reduced the incidence of restenosis and resultant target vessel revascularization (2), a low rate of ISR continues to exist and it is not benign. Outcomes are even poorer for those with DES compared with individuals presenting with BMS-ISR (3).. There are several treatment options for DES-ISR (e.g., repeat percutaneous coronary ...

BACKGROUND: There is paucity of data regarding the clinical outcome of second generation drug- eluting stents (DES) post rotational atherectomy (RA) for heavily calcified coronary lesions (HCCL). METHODOLOGY: The study cohort comprised 99 (116 lesions) consecutive patients who underwent RA for HCCL at our institution and received either a first generation DES (40 patients, 53 lesions) or a second generation DES (59 patients, 63 lesions). The analyzed clinical parameters were the 12-month rates of death (all cause and cardiac), Q-wave MI, target lesion revascularization (TLR), definite stent thrombosis (ST) and major adverse cardiac events (MACE) defined as the composite of death, Q-wave MI, or TLR. RESULTS: The two groups were well matched for their baseline characteristics except for a lower left ventricular ejection fraction in the second generation DES group (46.0±23.0% vs. 55.0±9.0%; p=0.02). The group receiving second generation DES had more type C lesions (81.0% vs. 58.8%; p=0.01), ...

Since the drug eluting stents have provided better results concerning restenosis and repeat revascularization comparing to bare metal stents, percutaneous coronary interventions are performing increasingly in more complex stenoses. However, drug eluting stents did not show any advantage on prevention of myocardial infarction and survival. Currently there is no any completed controlled randomized study showing the superiority or equality of drug eluting stents over coronary bypass surgery by means of efficacy and safety. While the long-term results of drug eluting stents still unclear, everyday progressively more patients with multivessel disease are undergoing percutaneous coronary intervention with drug eluting stent implantation. The aim of this review is to discuss the efficacy and safety of drug eluting stents in patients with multivessel disease.. Keywords: Coronary artery disease, stent, drug-eluting stent, multivessel disease, coronary bypass ...

Global Drug-Eluting Stents Market 2025 Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2025 is Provided to Determine the Market Potential.. Drug eluting stents are tubular mesh-like structures of thin wires that are placed inside coronary arteries during percutaneous coronary interventions (PCIs) to help treat acute myocardial infarction, atherosclerosis, angina pectoris, and other coronary disorders. Presently, a wide range of stents are available in the global drug eluting stents market due to technological advancements leading to their incorporation into stenting technologies. Drug eluting stents are made of metal coated with a pharmacologic agent, which is known to suppress restenosis. These stents have proven to be efficient in the treatment of acute myocardial infraction, angina pectoris, multiple vessel disease, and atherosclerosis. Drug eluting stents have ...

Drug-eluting balloon for in-stent restenosis Yin Chen, Shilian Hu, Lei Wu To the Editor: We read with interest the meta-analysis by Indermuehle A et al which reported that drug-eluting balloon (DEB) appears to show great promise for in-stent restenosis (ISR), and could reduce the risk for major adverse cardiac events (MACE) compared with plain balloon angioplasty (BA)or implantation of drug-eluting stent (DES) in the treatment of ISR (1).Coronary ISR, happened after coronary stent implantation, continued to be a major problem. The authors raised a critical concern assessing the effectiveness of DEB, and long-term outcomes were adequately discussed in the article. Actually, for the PACCOCATH (Treatment of ISR by Paclitaxel Coated PTCA Balloon) trial, the short-term outcomes were not identified in the meta- analysis (2, 3), and the subgroup analysis according to control group (BA or DES) was only adopted for late lumen loss. DEB appears to be more effective in the reduction of binary restenosis ...

With Habib Samady, MD, and John Wang, MD, MSc. In this edition of our Conversations with Experts series, Habib Samady, MD, director of interventional cardiology and the cardiac catheterization laboratory at Emory University Hospital in Atlanta, speaks with John Wang, MD, MSc, chief of the cardiac catheterization laboratory at MedStar Union Memorial Hospital in Baltimore, about the current and future role of bare-metal stents in the interventional cardiology landscape. Dr. Wang was the national principal investigator of the OMEGA trial, the results from which led to the FDA approval of the REBEL™ Platinum Chromium Coronary Stent System (Boston Scientific Corporation; Natick, Massachusetts).. John Wang, MD, MSc: Dr. Samady, let me first ask you: what percentage of the time do you use drug-eluting stents versus bare-metal stents in your practice? Habib Samady, MD: At Emory University Hospital, we probably use drug-eluting stents 85% of the time and bare-metal stents 15% of the time. Dr. Wang: ...

A Prospective Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS element) for the Treatment of up to Two De Novo Coronary Artery Lesions - PLATINUM Trial

TY - JOUR. T1 - Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation a randomized, controlled trial. AU - Lee, Cheol Whan. AU - Ahn, Jung Min. AU - Park, Duk Woo. AU - Kang, Soo Jin. AU - Lee, Seung Whan. AU - Kim, Young Hak. AU - Park, Seong Wook. AU - Han, Seungbong. AU - Lee, Sang Gon. AU - Seong, In Whan. AU - Rha, Seung Woon. AU - Jeong, Myung Ho. AU - Lim, Do Sun. AU - Yoon, Jung Han. AU - Hur, Seung Ho. AU - Choi, Yun Seok. AU - Yang, Joo Young. AU - Lee, Nae Hee. AU - Kim, Hyun Sook. AU - Lee, Bong Ki. AU - Kim, Kee Sik. AU - Lee, Seung Uk. AU - Chae, Jei Keon. AU - Cheong, Sang Sig. AU - Suh, Il Woo. AU - Park, Hun Sik. AU - Nah, Deuk Young. AU - Jeon, Doo Soo. AU - Seung, Ki Bae. AU - Lee, Keun. AU - Jang, Jae Sik. AU - Park, Seung Jung. PY - 2014/1/21. Y1 - 2014/1/21. N2 - Background-The risks and benefits of long-term dual antiplatelet therapy remain unclear. Methods and Results-This prospective, multicenter, open-label, randomized comparison trial was ...

In the first-in-human study, 50 patients with in-stent restenosis (following either a drug-eluting stent or bare metal stent) underwent coronary angioplasty with the Virtue balloon. The primary safety endpoint was the 30-day rate of target lesion failure-a composite of cardiac death, target vessel myocardial infarction, and clinically-driven target lesion revascularisation-and the primary performance endpoint was in-stent late lumen loss at six months.. Results. Verheye et al comment: No target lesion failures were reported through the 30-day follow-up for the entire 50 patient study population. Among the 49 intention-to-treat patients at the six month follow-up, one underwent coronary artery bypass and four received target lesion revascularisation for a target lesion failure rate of 8.2% and major adverse cardiac event rate of 10.2%. They add that in-segment late lumen loss was 0.31±0.52mm which met the established criteria for superiority to historical plain balloon angioplasty values ...

Results from the PRISON IV Trial Presented at TCT 2016 and Simultaneously Published in JACC: Cardiovascular Interventions. WASHINGTON - November 2, 2016 - Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a biodegradable polymer compared to thin-strut everolimus-eluting stents (Xience EES) with a durable polymer in terms of in-segment late lumen loss in successfully treated chronic total occlusions. In addition, although the rate of binary restenosis was low overall in this complex lesion subset, it was higher with the Osirio SES compared with the Xience EES.. Findings from the PRISON IV trial were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the worlds premier educational meeting specializing in interventional cardiovascular medicine. The study was also published in the ...

Background: It is important to determine the best drug-eluting stent (DES) for acute myocardial infarction (AMI) in patients with renal impairment. In this studythe outcomes of everolimus-eluting stents (EESs), zotarolimus-eluting stents (ZESs) and biolimus-eluting stents (BESs) were evaluated.. Methods: From the Korea Acute Myocardial Infarction-National Institutes of Health registry, a total of 1,470 AMI patients with renal impairment undergoing percutaneous coronary intervention (PCI) were enrolled (816 with EES, 345 with ZES, and 309 with BES). Renal impairment was defined as creatinine clearance , 60 mL/min/1.73 m2 estimated by the Cockcroft-Gault method. Major adverse cardiac and cerebrovascular events were determined as the composite of all-cause death, non-fatal myocardial infarction (MI), cerebrovascular accident, any revascularization, rehospitalization and stent thrombosis. All clinical outcomes were analyzed.. Results: The baseline characteristics of the patients revealed no ...

OBJECTIVES: To compare the efficacy and safety of drugeluting stents (DES) vs. bare-metal stents (BMS) in patients with acute ST-segment-elevation myocardial infarction (STEMI). BACKGROUND: DES effectively reduce restenosis in elective percutaneous c

This head-to-head trial will assess the non-inferiority of NEVO sirolimus-eluting stent to the XIENCE V everolimus-eluting stent for the prevention of coronary

Patients with diabetes mellitus have less favourable outcomes after percutaneous coronary intervention (PCI) than non-diabetics. We performed a subgroup analysis of the multicentre RAVEL trial to examine the impact of the sirolimus-eluting stent (SES) on outcomes in diabetic patients. The RAVEL study randomized 238 patients to treatment with either sirolimus-eluting or bare metal stents. Forty-four patients were diabetic; 19 received sirolimus-eluting stents and 25 were treated with bare metal stents. The differences in outcomes between diabetic and non-diabetic patients treated with SES (n=101) were also assessed. Follow-up angiography was performed at 6 months. Major adverse cardiac events (MACE) defined as death, myocardial infarction (MI), or target lesion revascularization (TLR) were analysed at 12-month follow-up. Six-month in-stent late lumen loss was significantly lower for the diabetic SES than the bare stent group (0.07+/-0.2 vs 0.82+/-0.5mm; P,0.001) and similar to that in ...

TY - JOUR. T1 - Impact of angiographic residual stenosis on clinical outcomes after new-generation drug-eluting stents implantation. T2 - Insights from a pooled analysis of the RESET and NEXT trials. AU - RESET and NEXT Investigators. AU - Watanabe, Hiroki. AU - Morimoto, Takeshi. AU - Shiomi, Hiroki. AU - Natsuaki, Masahiro. AU - Kawai, Kazuya. AU - Kozuma, Ken. AU - Igarashi, Keiichi. AU - Kadota, Kazushige. AU - Tanabe, Kengo. AU - Morino, Yoshihiro. AU - Hibi, Kiyoshi. AU - Akasaka, Takashi. AU - Abe, Mitsuru. AU - Suwa, Satoru. AU - Muramatsu, Toshiya. AU - Kobayashi, Masakazu. AU - Dai, Kazuoki. AU - Nakao, Koichi. AU - Tarutani, Yasuhiro. AU - Fujii, Kenshi. AU - Kimura, Takeshi. N1 - Funding Information: The RESET study was supported by Abbott Vascular Japan, and the NEXT study was supported by Terumo. Publisher Copyright: © 2018 The Authors.. PY - 2018/7/1. Y1 - 2018/7/1. N2 - Background-Previous intravascular ultrasound studies suggested the association of stent underexpansion with ...

In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years. (Funded by Abbott Vascula …

This head-to-head noninferiority trial is comparing the efficacy and tolerability of a platinum chromium everolimus-eluting coronary stent system [PROMUS

PRACTICAL RECOMMENDATIONS ON ANTI-THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS. Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista

Approximately 70 percent of angioplasty procedures also involve stenting, which is the insertion of a small metal cylinder called a stent into a blood vessel. In this procedure, a collapsed stent is placed over the balloon at the tip of the catheter. When the balloon inflates, the stent pops open and reinforces the artery walls. The balloon and catheter are then withdrawn and the stent remains permanently. In a few weeks, tissue from the artery lining grows over the stent.. There are two types of stents. Bare-metal stents are plain, untreated metal cylinders. Drug-eluting stents (also called drug-coated stents) are coated with medication before they are placed in the artery. This medication helps prevent scarring and lowers the risk for restenosis (re-narrowing of the artery). Drug-eluting stents may present a higher risk for blood clot formation than bare-metal stents. ...

Pubmed.ncbi.nlm.nih.gov DA: 23 PA: 10 MOZ Rank: 47. Objectives: This study sought to report the final 5-year outcomes of the ENDEAVOR IV (A Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) trial comparing the Endeavor zotarolimus-eluting stent (E-ZES) (Medtronic, Santa Rosa, California) with … ...

The optimal revascularization strategy of coronary artery bypass grafting (CABG) versus percutaneous coronary intervention with drug-eluting stent (PCI-DES) in patients with chronic kidney disease (CKD) and multivessel disease (MVD) remains unclear.. ...

The drug-eluting balloon (DEB) is a device that is used to reduce the risk of repeat stent implantation in patients with in-stent restenosis (ISR) (1). Characterization of tissue by optical coherence tomography (OCT) may provide useful information to identify good candidates for DEBs (2). However, the image visualized by OCT just after DEB dilation is unclear. We present images after DEB dilation visualized by OCT.. A 45-year-old man was treated with a bare metal stent (BMS) (S-stent 4.0/23.0 mm) implanted in the right coronary artery (RCA) for acute ST-segment elevation myocardial infarction. After percutaneous coronary intervention (PCI), he was taking 100 mg of aspirin and 75 mg of clopidogrel. However, a second coronary angiography at 6 months after BMS implantation showed ISR in the BMS. A repeat PCI was performed for ISR in the RCA. After the guide wire was advanced to the distal portion of the RCA, the target lesion was dilated using a 4.0/13.0 mm scoring balloon catheter (Lacrosse ...

TY - JOUR. T1 - 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. AU - Galløe, Anders M. AU - Kelbæk, Henning. AU - Thuesen, Leif. AU - Hansen, Henrik S.. AU - Ravkilde, Jan. AU - Hansen, Peter R. AU - Christiansen, Evald H. AU - Abildgaard, Ulrik. AU - Stephansen, Ghita. AU - Lassen, Jens F. AU - Engstrøm, Thomas. AU - Jensen, Jan Skov. AU - Jeppesen, Jørgen L. AU - Bligaard, Niels. AU - SORT OUT II Investigators. N1 - Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.. PY - 2017/2/14. Y1 - 2017/2/14. KW - Journal Article. U2 - 10.1016/j.jacc.2016.11.055. DO - 10.1016/j.jacc.2016.11.055. M3 - Journal article. C2 - 28183505. VL - 69. SP - 616. EP - 624. JO - Journal of the American College of Cardiology. JF - Journal of the American College of Cardiology. SN - 0735-1097. IS - 6. ER - ...